Analysis of the landscape of biologically-derived pharmaceuticals in Europe: Dominant production systems, molecule types on the rise and approval trends

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 3, 2013, Pages 428-441

  Sarantos, Kyriakopoulos ^a   Cleo, Kontoravdi ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

European medicines agency; Host cells; RDNA drugs; Therapeutic area; Therapeutic molecule class

Indexed keywords

BECAPLERMIN; COLONY STIMULATING FACTOR; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; GENERIC DRUG; GLYCOPROTEIN; HUMAN GROWTH HORMONE; IMMUNOSTIMULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT VACCINE; RIBOSOME DNA; ROMIPLOSTIM; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SOMATOMEDIN C; BIOLOGICAL PRODUCT; NEW DRUG;

CELL CULTURE; DRUG ANALYSIS; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG MANUFACTURE; DRUG SCREENING; DRUG SYNTHESIS; EUROPE; GLYCOSYLATION; IMMUNOGENICITY; MAMMAL CELL; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; EUROPEAN UNION; HUMAN; PHARMACEUTICS; TRENDS;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG APPROVAL; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; EUROPE; EUROPEAN UNION; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84872410762     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.11.016     Document Type: Review

References (70)

1. Aggarwal, S., 2007. What's fueling the biotech engine? Nat. Biotechnol. 25 (10), 1097-1104.
2. Aggarwal, S., 2008. What's fueling the biotech engine-2007. Nat. Biotechnol. 26 (11), 1227-1233.
3. Aggarwal, S., 2009. What's fueling the biotech engine-2008. Nat. Biotechnol. 27 (11), 987-993.
4. Aggarwal, S., 2010. What's fueling the biotech engine-2009-2010. Nat. Biotechnol. 28 (11), 1165-1171.
5. Aggarwal, S., 2011. What's fueling the biotech engine-2010 to 2011. Nat. Biotechnol. 29 (12), 1083-1089.
6. Blijlevens, N., Sonis, S., 2007. Palifermin (recombinant keratinocyte growth factor-1): A pleiotropic growth factor with multiple biological activities in preventing chemotherapy-and radiotherapy-inducedmucositis. Ann. Oncol. 18 (5), 817-826.
7. Bokemeyer, C., 2010. Catumaxomab-trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin. Biol. Ther. 10 (8), 1259-1269.
8. Borden, E.C. et al., 2003. Soft tissue sarcomas of adults: State of the translational science. Clin. Cancer Res. 9 (6), 1941-1956.
9. Bouton, M.C. et al., 2012. Emerging role of serpinE2/protease nexin-1 in hemostasis and vascular biology. Blood 119 (11), 2452-2457.
10. Brashear, A. et al., 1999. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53 (7), 1439-1446.
11. Bresnihan, B. et al., 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41 (12), 2196-2204.
12. Danforth Jr., E., Burger, A.G., 1989. The impact of nutrition on thyroid hormone physiology and action. Annu. Rev. Nutr. 9, 201-227.
13. Davis, B., Bernstein, J.A., 2011. Conestat alfa for the treatment of angioedema attacks. Ther. Clin. Risk Manage. 7, 265-273.
14. Desnick, R.J., Schuchman, E.H., 2012. Enzyme replacement therapy for lysosomal diseases: Lessons from 20 years of experience and remaining challenges. Annu. Rev. Genomics Hum. Genet. 13, 307-335.
15. Dhib-Jalbut, S., Marks, S., 2010. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 74 (Suppl. 1), S17-S24.
16. Elvin, J.G., Couston, R.G., van der Walle, C.F., 2011. Therapeutic antibodies: Market considerations, disease targets and bioprocessing. Int. J. Pharm.
17. Ferrer-Miralles, N. et al., 2009. Microbial factories for recombinant pharmaceuticals. Microb. Cell Fact. 8, 17.
18. Fisher, D.A., 1996. Physiological variations in thyroid hormones: Physiological and pathophysiological considerations. Clin. Chem. 42 (1), 135-139.
19. Fleischmann, R.M. et al., 2006. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65 (8), 1006-1012.
20. Giangrande, P.L., 2003. Six characters in search of an author: The history of the nomenclature of coagulation factors. Br. J. Haematol. 121 (5), 703-712.
21. Gilpin, D. et al., 2010. Injectable collagenase Clostridium histolyticum: A new nonsurgical treatment for Dupuytren's disease. J. Hand. Surg. Am. 35 (12), 2027-2038 e1.
22. Goldenberg, N.A., Manco-Johnson, M.J., 2008. Protein C deficiency. Haemophilia 14 (6), 1214-1221.
23. Hamilton, S.R. et al., 2006. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313 (5792), 1441-1443.
24. Hochberg, J., Cairo, M.S., 2008. Rasburicase: Future directions in tumor lysis management. Expert Opin. Biol. Ther. 8 (10), 1595-1604.
25. Hunt, L.T., Dayhoff, M.O., 1980. A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha 1-proteinase inhibitor. Biochem. Biophys. Res. Commun. 95 (2), 864-871.
26. Isaksson, O.G., Eden, S., Jansson, J.O., 1985. Mode of action of pituitary growth hormone on target cells. Annu. Rev. Physiol. 47, 483-499.
27. Jefferis, R., 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8 (3), 226-234.
28. Jimenez del Val, I., Kontoravdi, C., Nagy, J.M., 2010. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol. Prog. 26 (6), 1505-1527.
29. Kieffer, T.J., Habener, J.L., 1999. The glucagon-like peptides. Endocr. Rev. 20 (6), 876-913.
30. Kirkwood, J., 2002. Cancer immunotherapy: The interferon-alpha experience. Semin. Oncol. 29 (3 Suppl. 7), 18-26.
31. Kopchick, J.J. et al., 2002. Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly. Endocr. Rev. 23 (5), 623-646.
32. Kraenzlin, M.E., Meier, C., 2011. Parathyroid hormone analogues in the treatment of osteoporosis. Nat. Rev. Endocrinol. 7 (11), 647-656.
33. Krantz, S.B., 1991. Erythropoietin. Blood 77 (3), 419-434.
34. Kuter, D.J., 2008. New drugs for familiar therapeutic targets: Thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur. J. Haematol. 69, 9-18.
35. Laflamme, C., Rouabhia, M., 2008. Effect of BMP-2 and BMP-7 homodimers and a mixture of BMP-2/BMP-7 homodimers on osteoblast adhesion and growth following culture on a collagen scaffold. Biomed. Mater. 3 (1).
36. Lambris, J.D., Ricklin, D., Geisbrecht, B.V., 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6 (2), 132-142.
37. Ledford, H., 2007. Biotechs go generic: The same but different. Nature 449 (7160), 274-276.
38. Lew, W.K., Weaver, F.A., 2008. Clinical use of topical thrombin as a surgical hemostat. Biol.: Targets Ther. 2 (4), 593.
39. Lewiecki, E.M., Bilezikian, J.P., 2012. Denosumab for the treatment of osteoporosis and cancer-related conditions. Clin. Pharmacol. Ther. 91 (1), 123-133.
40. Lidove, O. et al., 2012. Fabry disease 'The New Great Imposter': Results of the French Observatoire in Internal Medicine Departments (FIMeD). Clin. Genet. 81 (6), 571-577.
41. Mannucci, P.M., 2003. Hemophilia: Treatment options in the twenty-first century. J. Thromb. Haemost. 1 (7), 1349-1355.
42. Maritim, A.C., Sanders, R.A., Watkins 3rd, J.B., 2003. Diabetes, oxidative stress, and antioxidants: A review. J. Biochem. Mol. Toxicol. 17 (1), 24-38.
43. Monroe, D.M., 2012. Factor VIIa: On its own and loving it. Blood 120 (4), 705-707.
44. Newman, D.J., Cragg, G.M., 2007. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70 (3), 461-477.
45. Newman, D.J., Cragg, G.M., 2012. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75 (3), 311-335.
46. Newman, D.J., Cragg, G.M., Snader, K.M., 2003. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66 (7), 1022-1037.
47. Ng, S.K., 2012. Current cell-based Influenza vaccine production technology as pandemic contingency. Human Vaccines Immunotherapeutics 8 (2).
48. Panicker, L.M. et al., 2012. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc. Natl. Acad. Sci. USA 109 (44), 18054-18059.
49. Raju, T.S., 2008. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 20 (4), 471-478.
50. Rodgers, G.M., 2009. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. Thromb. Haemost. 101 (5), 806-812.
51. Rollman, O. et al., 2003. Platelet derived growth factor (PDGF) responsive epidermis formed from human keratinocytes transduced with the PDGF beta receptor gene. J. Invest. Dermatol. 120 (5), 742-749.
52. Rorsman, P., 2005. Review: Insulin secretion: Function and therapy of pancreatic beta-cells in diabetes. Br. J. Diabetes Vasc. Dis. 5 (4), 187-191.
53. Schlaeppi, J.M. et al., 1990. Preparation of monoclonal antibodies to hirudin and hirudin peptides. A method for studying the hirudin-thrombin interaction. Eur. J. Biochem. 188 (2), 463-470.
54. Seegers, W.H. et al., 1976. Relationship of "new" vitamin K-dependent Protein C and "old" autoprothrombin II-a. Thromb. Res. 8 (5), 543-552.
55. Sheehan, J.J., Tsirka, S.E., 2005. Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: A review. Glia 50 (4), 340-350.
56. Van Sickels, N.J., Hunsaker, R.B., Van Sickels, J.E., 2010. Hereditary angioedema: Treatment, management, and precautions in patients presenting for dental care. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 109 (2), 168-172.
57. Sims, J.E. et al., 1993. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc. Natl. Acad. Sci. USA 90 (13), 6155-6159.
58. Sola, R.J., Griebenow, K., 2009. Effects of glycosylation on the stability of protein pharmaceuticals. J. Pharm. Sci. 98 (4), 1223-1245.
59. Strebhardt, K., Ullrich, A., 2008. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8 (6), 473-480.
60. Tracey, K.J., Cerami, A., 1994. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45, 491-503.
61. Turgeon, V.L., Houenou, L.J., 1997. The role of thrombin-like (serine) proteases in the development, plasticity and pathology of the nervous system. Brain Res. Brain Res. Rev. 25 (1), 85-95.
62. van Horssen, R., Ten Hagen, T.L., Eggermont, A.M., 2006. TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 11 (4), 397-408.
63. Walker, J.L. et al., 1991. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). N. Engl. J. Med. 324 (21), 1483-1488.
64. Waller, C.F., 2012. Critical appraisal of biosimilar filgrastim (Nivestim™) for febrile and chemotherapy-induced neutropenia. Biosimilars 2, 1-11.
65. Walsh, G., 2010. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28 (9), 917-924.
66. Wang, J., Chow, S.C., 2012. On the regulatory approval pathway of biosimilar products. Pharmaceuticals 5 (4), 353-368.
67. Weclawiak, H. et al., 2010. Biological agents in kidney transplantation: Belatacept is entering the field. Expert Opin. Biol. Ther. 10 (10), 1501-1508.
68. Wood, P., 2012. Human normal immunoglobulin in the treatment of primary immunodeficiency diseases. Ther. Clin. Risk Manage. 8, 157-167.
69. Wright, A., Morrison, S.L., 1997. Effect of glycosylation on antibody function: Implications for genetic engineering. Trends Biotechnol. 15 (1), 26-32.
70. Wurster-Hill, D.H. et al., 1988. Cytogenetic studies in Dupuytren contracture. Am. J. Hum. Genet. 43 (3), 285-292.